Praxis Precision Medicines, Inc.（以下简称"Praxis"）今日宣布，其研发药物盐酸乌利沙卡酰胺（Ulixacaltamide Hcl）已获得美国食品药品监督管理局（FDA）授予的突破性疗法认定，适应症为原发性震颤。
该认定基于临床数据表明该药物相较于现有疗法可能展现出显著优势。突破性疗法资格将加速药物研发与审评进程，为患者提供更早获得创新治疗的机会。
Praxis Precision Medicines, Inc.（以下简称"Praxis"）今日宣布，其研发药物盐酸乌利沙卡酰胺（Ulixacaltamide Hcl）已获得美国食品药品监督管理局（FDA）授予的突破性疗法认定，适应症为原发性震颤。
该认定基于临床数据表明该药物相较于现有疗法可能展现出显著优势。突破性疗法资格将加速药物研发与审评进程，为患者提供更早获得创新治疗的机会。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.